



Movymia

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
N/0028	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	12/01/2022		PL	
IB/0030/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release	08/12/2021	n/a		

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place				
IB/0029	B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation	02/12/2021	n/a		
R/0024	Renewal of the marketing authorisation.	22/07/2021	16/09/2021	SmPC, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Movymia in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. The RMP has been also updated (version 2.2).
N/0025	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	13/08/2021		Labelling and PL	
IA/0026/G	This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	09/08/2021	n/a		
N/0023	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	15/03/2021	16/09/2021	PL	

IB/0022/G	<p>This was an application for a group of variations.</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p>	11/01/2021	n/a		
II/0020	B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products	17/09/2020	16/09/2021	SmPC, Annex II, Labelling and PL	
IAIN/0021	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	10/07/2020	n/a		
IB/0018/G	<p>This was an application for a group of variations.</p> <p>B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS</p> <p>B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation</p> <p>B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits</p>	05/05/2020	n/a		

IAIN/0019	B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking	10/04/2020	n/a		
IB/0016	B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation	08/01/2020	n/a		
N/0015	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	06/12/2019	13/05/2020	PL	
IA/0014	B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information	26/06/2019	n/a		
II/0010	Submission of the final clinical study report from Study RGB1023031; a Phase III, multi-centre, randomised, active-controlled, parallel-group, comparative efficacy/safety study. An updated RMP version 1.4 was agreed during the procedure. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	14/06/2019	n/a		n/a
IB/0011	B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging -	28/05/2019	13/05/2020	SmPC, Labelling and PL	

	Device with CE marking				
IA/0013	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	24/05/2019	n/a		
II/0012	B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products	23/05/2019	n/a		
PSUSA/2903/201809	Periodic Safety Update EU Single assessment - teriparatide	16/05/2019	n/a		PRAC Recommendation - maintenance
IA/0008	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	12/12/2018	n/a		
N/0007	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	11/12/2018	13/05/2020	PL	
IB/0006/G	This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder	30/10/2018	n/a		

	<p>or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient</p> <p>B.I.z - Quality change - Active substance - Other variation</p> <p>B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place</p> <p>B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure</p> <p>B.III.2.a.2 - Change of specification(s) of a former non EU Pharmacopoeial substance to fully comply with the Ph. Eur. or with a national pharmacopoeia of a Member State - Excipient/AS starting material</p>				
IB/0005	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	19/02/2018	19/04/2018	SmPC and PL	
N/0004	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	13/07/2017	19/04/2018	PL	
IB/0002/G	<p>This was an application for a group of variations.</p> <p>B.I.a.2.z - Changes in the manufacturing process of</p>	05/04/2017	n/a		

	the AS - Other variation B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data				
IA/0001	A.z - Administrative change - Other variation	05/04/2017	19/04/2018	SmPC, Labelling and PL	